High-risk and real-world patients responded
Study explores atezolizumab for myelodysplastic syndrome
FDA approval may come in 2019
Lower toxicity than conventional chemo
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
New recommendations for second-line therapy
Groundbreaking study paves way for targeted therapy
Rationale and status reports on mechanistically varied strategies
Gene signatures differentiate clinical response
10-year outcomes favor autologous over implant
Initial study results are encouraging
Advertisement
Advertisement